@article{article, title  = {{Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial}},

 publisher = {{Oxford University Press (OUP)}},

 url = {{http://dx.doi.org/10.1093/bjd/ljad240 }},

 year = {{2023}},

 month = {{7}},

 author = {{Weidinger S and Bieber T and Cork MJ and Reich A and Wilson R and Quaratino S and Stebegg M and Brennan N and Gilbert S and O’Malley JT and Porter-Brown B}},

 doi = {{10.1093/bjd/ljad240}},

 volume = {{189}},

 journal = {{British Journal of Dermatology}},

 issue = {{5}},

 pages = {{531-539}},

 note = {{Accessed on 2024/12/22}}}